A post-marketing disproportionality analysis of the safety of ribociclib based on the FDA Adverse Event Reporting System
{{output}}
Background: Although there are reports of adverse events (AEs) of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, the safety of ribociclib alone has not yet been comprehensively evaluated in real-world clinical practice. ... ...
